Healthcare-Associated Ventriculitis and Meningitis

Publication Date: February 27, 2017

Diagnosis

Typical Symptoms and Signs

Cerebrospinal Fluid (CSF) Shunts and Drains

New headache, nausea, lethargy and/or change in mental status are suggestive of CSF shunt infection. ( S , M)
705
Erythema and tenderness over the subcutaneous shunt tubing are suggestive of CSF shunt infection. ( S , M)
705
Fever, in the absence of another clear source of infection, could be suggestive of CSF shunt infection. ( W , L)
705
Symptoms and signs of peritonitis or abdominal tenderness in patients with ventriculoperitoneal shunts, in the absence of another clear etiology, are indicative of CSF shunt infection. ( S , M)
705
Symptoms and signs of pleuritis in patients with ventriculopleural shunts, in the absence of another clear etiology, are indicative of CSF shunt infection. ( S , M)
705
Demonstration of bacteremia in a patient with a ventriculoatrial shunt, in the absence of another clear source of bacteremia, is evidence of CSF shunt infection. ( S , M)
705
Demonstration of glomerulonephritis in a patient with a ventriculoatrial shunt is suggestive of CSF shunt infection. ( W , L)
705
New or worsening altered mental status in patients with external ventricular drains is suggestive of infection. ( W , L)
705
New fever and increased CSF white blood cell count in patients with external ventricular drains could be suggestive of infection. ( W , L)
705

Neurosurgery or Head Trauma

New headache, fever, evidence of meningeal irritation, seizures and/or worsening mental status are suggestive of ventriculitis or meningitis in the setting of recent trauma or neurosurgery. ( S , M)
705
Fever, in the absence of another clear source of infection, is suggestive of central nervous system (CNS) infection in the setting of recent head trauma or neurosurgery. ( W , L)
705

Intrathecal Infusion Pumps

New fever and drainage from the surgical site in patients with intrathecal infusion pumps are suggestive of wound infection. ( W , L)
705

Typical Cerebrospinal Fluid Findings

Cell Count, Glucose and Protein

Abnormalities of CSF cell count, glucose and/or protein may not be reliable indicators for the presence of infection in patients with healthcare-associated ventriculitis and meningitis. ( W , M)
705
Normal CSF cell count, glucose and protein may not reliably exclude infection in patients with healthcare-associated ventriculitis and meningitis. ( W , M)
705
A negative CSF Gram stain does not exclude the presence of infection, especially in patients who have received previous antimicrobial therapy ( S , M)
705

Culture

CSF cultures are the most important test to establish the diagnosis of healthcare-associated ventriculitis and meningitis. ( S , H)
705
If initial CSF cultures are negative in patients with CSF shunts or drains with suspected infection, it is recommended that cultures should be held for at least 10 days in an attempt to identify organisms such as Propionibacterium acnes. ( S , H)
705
If a CSF shunt or drain is removed in patients suspected of having infection, cultures of shunt and drain components are recommended. ( S , M)
705
If a CSF shunt or drain is removed for indications other than infection, cultures of shunt or drain components are NOT recommended. ( S , M)
705
Blood cultures are recommended in patients with suspected ventriculoatrial shunt infections. (S, H)
705
Blood cultures may be considered in patients with ventriculoperitoneal and ventriculopleural shunts (W, L)
705
Single or multiple positive CSF cultures in patients with CSF pleocytosis and/or hypoglycorrhachia, or an increasing cell count, and clinical symptoms suspicious for ventriculitis or meningitis, is indicative of CSF drain infection. (S, H)
705
CSF and blood cultures in selected patients should be obtained before the administration of antimicrobial therapy. A negative CSF culture in the setting of previous antimicrobial therapy does not exclude healthcare-associated ventriculitis and meningitis (S, M)
705

Neurosurgery or Head Trauma

CSF pleocytosis with a positive culture and symptoms of infection are indicative of a diagnosis of healthcare-associated ventriculitis or meningitis (S, H)
705
Hypoglycorrhachia and elevated CSF protein concentrations are suggestive of the diagnosis of healthcare-associated ventriculitis or meningitis. ( W , L)
705
Growth of an organism which is commonly considered a contaminant (e.g., coagulase-negative Staphylococcus) in enrichment broth only or on just one of multiple cultures, in a patient with normal CSF and no fever, is not indicative of healthcare-associated ventriculitis or meningitis. ( S , L)
705
CSF cultures with multiple organisms from a single sample may be contaminants in patients with no symptoms of infection or CSF pleocytosis. ( W , L)
705
CSF cultures that grow Staphylococcus aureus or aerobic gram-negative bacilli are indicative of infection. ( S , M)
705
CSF cultures that grow a fungal pathogen are indicative of infection. ( S , M)
705

Specific CSF Tests to Confirm the Diagnosis

An elevated CSF lactate or an elevated CSF procalcitonin, or the combination of both, may be useful in the diagnosis of healthcare-associated bacterial ventriculitis and meningitis. ( W , M)
705
An elevated serum procalcitonin may be useful in differentiating between CSF abnormalities due to surgery or intracranial hemorrhage from those due to bacterial infection. ( W , L)
705
Nucleic acid amplification tests, such as polymerase chain reaction (PCR), on CSF may both increase the ability to identify a pathogen and decrease the time to making a specific diagnosis. ( W , L)
705
Detection of β–D-glucan and galactomannan in CSF may be useful in the diagnosis of fungal ventriculitis and meningitis. ( S , M)
705

Imaging

Neuroimaging is recommended in patients with suspected healthcare-associated ventriculitis and meningitis. ( S , M)
705
Magnetic resonance imaging (MRI) with gadolinium-enhancement and diffusion-weighted imaging is recommended for detecting abnormalities in patients with healthcare-associated ventriculitis and meningitis. ( S , M)
705
In patients with infected ventriculoperitoneal shunts and abdominal symptoms (e.g., pain or tenderness), an ultrasound or computed tomography (CT) of the abdomen is recommended to detect CSF loculations at the shunt terminus. ( S , M)
705

Treatment

Empiric Antimicrobials

Vancomycin plus an anti-pseudomonal β-lactam (such as cefepime, ceftazidime or meropenem) is recommended as empiric therapy for healthcare-associated ventriculitis and meningitis. Choice of the empiric β-lactam agent should be based on local in vitro susceptibility patterns. ( S , L)
705
In seriously ill adult patients with healthcare-associated ventriculitis and meningitis, the vancomycin trough concentration should be maintained at 15–20 μg/mL in those receiving intermittent bolus administration. ( S , L)
705
For patients with healthcare-associated ventriculitis and meningitis who have experienced anaphylaxis to β-lactam antimicrobial agents and in whom meropenem is contraindicated, aztreonam or ciprofloxacin is recommended for gram-negative coverage ( S , L)
705
For patients with healthcare-associated ventriculitis and meningitis who are colonized or infected elsewhere with a highly antimicrobial-resistant pathogen, adjusting the empiric regimen to treat for this pathogen is recommended ( S , L)
705

Specific Antimicrobials

For treatment of infection caused by methicillin-susceptible Staphylococcus aureus, nafcillin or oxacillin is recommended. ( S , M)
705
If the patient cannot receive β-lactam agents, the patient can be desensitized or may receive vancomycin as an alternative agent. ( W , M)
705
For treatment of infection caused by methicillin-resistant S. aureus (MRSA), vancomycin is recommended as first line therapy, ( S , M)
705
with consideration for an alternative antimicrobial agent if the vancomycin MIC is ≥1 μg/mL. ( S , M)
705
For treatment of infection caused by coagulase-negative staphylococci, the recommended therapy should be similar to S. aureus and based on in vitro susceptibility testing. ( S , M)
705
If the staphylococcal isolate is susceptible to rifampin, this agent may be considered in combination with other antimicrobial agents for staphylococcal ventriculitis and meningitis. ( W , L)
705
Rifampin is recommended as part of combination therapy for any patient with intracranial or spinal hardware such as a CSF shunt or drain. ( S , L)
705
For treatment of patients with healthcare-associated ventriculitis and meningitis caused by staphylococci in whom β-lactam agents or vancomycin cannot be used, linezolid. ( S , L)
705
daptomycin ( S , L)
705
or trimethoprim-sulfamethoxazole ( S , L)
705
is recommended with selection of a specific agent based on in vitro susceptibility testing.
For treatment of infection caused by P. acnes, penicillin G is recommended. ( S , M)
705
For treatment of infection caused by gram-negative bacilli, therapy should be based on in vitro susceptibility testing with agents that achieve good CNS penetration. ( S , M)
705
For treatment of infection caused by gram-negative bacilli susceptible to third-generation cephalosporins, ceftriaxone or cefotaxime is recommended. ( S , M)
705
For treatment of infection caused by Pseudomonas species, the recommended therapy is cefepime, ceftazidime or meropenem. ( S , M)
705
Recommended alternative antimicrobial agents are aztreonam or a fluoroquinolone with in vitro activity. ( S , M)
705
For treatment of infection caused by extended spectrum β-lactamase (ESBL)-producing gram-negative bacilli, meropenem should be used if this isolate demonstrates in vitro susceptibility. ( S , M)
705
For treatment of infection caused by Acinetobacter species, meropenem is recommended. ( S , M)
705
For strains demonstrating carbapenem resistance, colistimethate sodium or polymyxin B (either agent administered by the intravenous and intraventricular routes) is recommended. ( S , M)
705
Prolonged infusion of meropenem (each dose administered over 3 hours) may be successful in treating resistant gram-negative organisms. ( W , L)
705
For treatment of infection caused by Candida species, based on in vitro susceptibility testing, liposomal amphotericin B, often combined with 5-flucytosine, is recommended. ( S , M)
705
Once the patient shows clinical improvement, therapy can be changed to fluconazole if the isolated species is susceptible. ( W , L)
705
For treatment of infection caused by Aspergillus or Exserophilum species, voriconazole is recommended. ( S , L)
705

Intraventricular Antimicrobial Therapy

Intraventricular antimicrobial therapy should be considered for patients with healthcare-associated ventriculitis and meningitis in which the infection responds poorly to systemic antimicrobial therapy alone. ( S , L)
705
When antimicrobial therapy is administered via a ventricular drain, the drain should be clamped for 15–60 minutes to allow the agent to equilibrate throughout the CSF. ( S , L)
705
Dosages and intervals of intraventricular antimicrobial therapy should be adjusted based on CSF antimicrobial concentrations to 10–20 times the MIC of the causative microorganism. ( S , L)
705
ventricular size, ( S , L)
705
and daily output from the ventricular drain. ( S , L)
705

Optimal Duration of Antimicrobial Therapy

Infections caused by a coagulase-negative Staphylococcus or P. acnes with no or minimal CSF pleocytosis, normal CSF glucose and few clinical symptoms or systemic features should be treated for 10 days. ( S , L)
705
Infections caused by a coagulase negative Staphylococcus or P. acnes with significant CSF pleocytosis, CSF hypoglycorrhachia or clinical symptoms or systemic features should be treated for 10–14 days. ( S , L)
705
Infections caused by S. aureus or gram-negative bacilli with or without significant CSF pleocytosis, CSF hypoglycorrhachia or clinical symptoms or systemic features should be treated for 10–14 days. ( S , L)
705
Some experts suggest treatment of infection caused by gram-negative bacilli for 21 days. ( W , L)
705
In patients with repeatedly positive CSF cultures on appropriate antimicrobial therapy, treatment should be continued for 10–14 after the last positive culture. ( S , L)
705

Catheter Removal

Complete removal of an infected CSF shunt and replacement with an external ventricular drain, combined with intravenous antimicrobial therapy, is recommended in patients with infected CSF shunts. ( S , M)
705
Removal of an infected CSF drain is recommended. ( S , M)
705
Removal of an infected intrathecal infusion pump is recommended. ( S , M)
705
Removal of infected hardware in patients with deep brain stimulation infections is recommended. ( S , M)
705

Patient Monitoring

Patients with healthcare-associated ventriculitis and meningitis should be monitored for response to treatment based on clinical parameters. ( S , L)
705
In patients with healthcare-associated ventriculitis and meningitis and an external drainage device, monitoring of CSF cultures is recommended to ensure that they become negative. ( S , L)
705
In patients with no definitive clinical improvement, additional CSF analysis is recommended to ensure that the CSF parameters have improved and the cultures become negative. ( S , L)
705
For external CSF drains not being used in the treatment of CSF shunt infection, daily CSF cultures and analysis are NOT recommended unless clinically indicated. ( S , L)
705

Shunt Reimplantion

In patients with infection caused by coagulase-negative staphylococci or P. acnes, with no associated CSF abnormalities and with negative CSF cultures for 48 hours after externalization, a new shunt should be reimplanted as soon as the third day after removal. ( S , L)
705
In patients with infection caused by a coagulase-negative Staphylococcus or P. acnes and associated CSF abnormalities but negative repeat CSF cultures, a new shunt should be reimplanted after 7 days of antimicrobial therapy. ( S , L)
705
If repeat cultures are positive, antimicrobial treatment is recommended until CSF cultures remain negative for 7–10 consecutive days before a new shunt is placed. ( S , L)
705
In patients with infection caused by S. aureus or gram-negative bacilli, a new shunt should be reimplanted 10 days after CSF cultures are negative. ( S , L)
705
A period off antimicrobial therapy is NOT recommended to verify clearing of the infection before shunt reimplantation. ( S , L)
705

Prevention

Periprocedural prophylactic antimicrobial administration is recommended for patients undergoing CSF shunt or drain insertion. ( S , M)
705
Periprocedural prophylactic antimicrobial administration is recommended for patients undergoing placement of external ventricular drains. ( S , M)
705
Prolonged antimicrobial prophylaxis for the duration of the external ventricular drain is of uncertain benefit and NOT recommended. ( S , M)
705
Use of antimicrobial-impregnated CSF shunts and CSF drains is recommended. ( S , M)
705
In patients with external ventricular drains, fixed interval exchange is NOT recommended. ( S , M)
705
Use of a standardized protocol for insertion of CSF shunts and drains is recommended. ( S , M)
705

Prophylactic Antimicrobial Therapy

For neurosurgical patients, perioperative antimicrobial agents are recommended to prevent infections of the incision. ( S , H)
705
In patients with basilar skull fractures and a CSF leak, prophylactic antimicrobial agents are NOT recommended. ( S , M)
705
In patients with basilar skull fractures and a prolonged CSF leakage (>7 days), an attempt to repair the leak is recommended. ( S , L)
705
In patients with basilar skull fractures and a CSF leak, pneumococcal vaccination is recommended. ( S , M)
705

Recommendation Grading

Disclaimer

Overview

Title

Healthcare-Associated Ventriculitis and Meningitis

Authoring Organization

Publication Month/Year

February 27, 2017

Supplemental Implementation Tools

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Inclusion Criteria

Female, Male, Adolescent, Adult, Child, Infant, Older adult

Health Care Settings

Hospital, Operating and recovery room

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Assessment and screening, Diagnosis, Prevention, Management, Treatment

Diseases/Conditions (MeSH)

D058565 - Cerebral Ventriculitis, D008581 - Meningitis

Keywords

meningitis, Ventriculitis, cerebrospinal fluid shunts, cerebrospinal fluid drains, CNS Infections, central nervous system infections

Source Citation

Allan R. Tunkel, Rodrigo Hasbun, Adarsh Bhimraj, Karin Byers, Sheldon L. Kaplan, W. Michael Scheld, Diederik van de Beek, Thomas P. Bleck, Hugh J. L. Garton, Joseph R. Zunt, 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis, Clinical Infectious Diseases, Volume 64, Issue 6, 15 March 2017, Pages 701–706, https://doi.org/10.1093/cid/cix152